Sotac Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2022 • Tablet: 78.7% • Capsules: 10.6% • Liquid: 7.1%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good sales growth of 27.7% CAGR over last 5 years
- Operating margins have improved to 14.1% from 8.7%
- Institutional investors have been accumulating - FII+DII up 7.8pp
- Attractively priced for its growth - PEG of 0.4
CONS
- Operating cash flow has been negative in recent years
- Receivables are growing faster than sales - a possible quality concern
- A large part of profit comes from other income (35.0% of PBT)
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.81x)
- Equity base is being diluted - shares outstanding up 380.4%
- Total debt has risen sharply - up 75.8% year on year
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SOTAC | 90.05 | 17.25 | 99.51 | 0.22 | 1.35 | — | 25.25 | 27.08 | 16.40 | 8.79 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2022 | Dec 2022 | Jun 2023 | Dec 2023 | Jun 2024 | |
|---|---|---|---|---|---|
| 20 | 20 | 25 | 26 | 25 | |
| 18 | 18 | 23 | 23 | 23 | |
| Operating Profit | 2 | 2 | 2 | 3 | 2 |
| OPM % | 9.65% | 9.02% | 9.37% | 11.31% | 8.79% |
| 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 0 | 1 | 1 | 1 | 1 |
| Profit before Tax | 1 | 1 | 2 | 1 | 1 |
| Tax % | 54.95% | 39.37% | 34.67% | 40.82% | -3.85% |
| Net Profit | 0 | 0 | 0 | 1 | 1 |
| 2.33 | 0.29 | 1.01 | 0.82 | 1.32 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 29 | 49 | 73 | 77 | 104 | 97 | 96 | |
| 27 | 47 | 67 | 70 | 96 | 83 | 86 | |
| Operating Profit | 2 | 1 | 6 | 7 | 8 | 14 | 9 |
| OPM % | 6.53% | 2.98% | 8.44% | 9.44% | 8.01% | 14.06% | 9.67% |
| 0 | 0 | 0 | 1 | 0 | 4 | 1 | |
| Interest | 0 | 1 | 1 | 2 | 2 | 3 | 2 |
| Depreciation | 1 | 3 | 1 | 2 | 3 | 4 | 3 |
| Profit before Tax | 0 | -2 | 5 | 4 | 4 | 11 | 5 |
| Tax % | 75.49% | -15.02% | 38.68% | 41.78% | 9.70% | 16.59% | 27.66% |
| Net Profit | 0 | -2 | 3 | 2 | 4 | 9 | 4 |
| EPS | 0.89 | -10.28 | 12.51 | 3.58 | 3.87 | 7.26 | — |
| Dividend Payout % | 0.00% | 0.00% | 15.98% | 0.00% | 0.00% | 1.38% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 28%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 147%
- 3 Years:
- 41%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -11%
- 1 Year:
- -28%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 7%
- 3 Years:
- 20%
- Last Year:
- 19%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 8 | 11 | 11 |
| Minority Interest | 2 | 0 | 0 | 0 | 4 | 5 |
| 1 | 0 | 4 | 2 | 34 | 42 | |
| 13 | 17 | 7 | 22 | 22 | 33 | |
| Trade Payables | 11 | 13 | 20 | 25 | 29 | 19 |
| 1 | 2 | 1 | 16 | 4 | 13 | |
| Total Liabilities | 30 | 35 | 35 | 74 | 104 | 123 |
| 16 | 17 | 9 | 26 | 36 | 49 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 5 | 0 |
| 0 | 0 | 0 | 0 | 2 | 4 | |
| 2 | 5 | 5 | 14 | 18 | 20 | |
| 0 | 0 | 0 | 0 | 26 | 34 | |
| Cash & Bank | 0 | 0 | 0 | 10 | 3 | 2 |
| 11 | 13 | 21 | 24 | 13 | 14 | |
| Total Assets | 30 | 35 | 35 | 74 | 104 | 123 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0 | 0 | 8 | 10 | -16 | -4 | |
| Cash from Investing | -12 | -3 | -4 | -12 | -20 | -14 |
| Cash from Financing | 11 | 3 | -3 | 13 | 29 | 16 |
| -0 | -0 | 0 | 10 | -6 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for SOTAC
Loading news…
AI Stock Analyst
Sotac Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account